Genelux (GNLX) Stock Analysis

What Genelux does

Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.

Key metrics

ETFs linked to GNLX

Broad-market and Healthcare sector ETFs an investor holding Genelux is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how GNLX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Genelux?

Genelux trades under the ticker GNLX on NASDAQ.

Which exchange is GNLX listed on?

GNLX is listed on NASDAQ.

What sector does Genelux operate in?

Genelux is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze GNLX in a portfolio?

PortView shows GNLX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.